Thanks for your feedback on the topic of ONCS's pipeline. If they are able to demonstrate responses in an anti-PD-1 nonresponder group, and they are able to treat visceral tumors through their proprietary EP device, then metastic melanoma is only the tip of the iceberg. In the meantime, the share price may continue its downward trend until there are more data.
At this point, I am simply not convinced that they are actually able to convert anti-PD-1 nonresponders into responders using the current IL-12 DNA construct and electroporation device. The 33% BORR advertised is for all checkpoint inhibitor nonresponders, not just anti-PD-1 nonresponders. That is, they aren't going for anti-CTLA-4 nonresponders in the PISCES trial. This is the biggest issue I have with the company right now. I don't feel comfortable with the existing data to give me much confidence in the PISCES trial.
With all this said, the P2A-linked data, TRACE-enabled device, and multigene constructs give me a lot of faith in the company's future. I also truly like the company's leadership. I think ONCS's intratumoral gene expression platform is the best approach to eliminating solid tumors. I think there is so much locked up value in this early stage work that it has become frustrating for me to see the company languish around a $20M valuation. I have invested literally thousands of hours researching cellular biology and combing through peer reviewed data and I gotta tell ya, as soon as ONCS figures out the right combinations of encoded proteins to drive immunity, things will change very quickly. I think anti-CTLA-4 needs to be encoded on a plasmid delivered and expressed intratumorally with P2A-linked IL-12 and a co-stimulator. That is in my unprofessional opinion, but it is an informed one.
